treatment-resistant depression

J&J’s Spravato Bests Quetiapine in Phase III Head-to-Head Depression Study
BioSpace
Thu, 10/5/23 - 10:14 am
JNJ
clinical trials
Spravato
treatment-resistant depression
depression
Quetiapine
Janssen’s Phase IIIb major depressive disorder trial meets primary endpoint
Clinical Trials Arena
Sat, 11/26/22 - 07:17 pm
Janssen
JNJ
clinical trials
Spravato
treatment-resistant depression
Biomind reports positive data from Phase II depression trial
Clinical Trials Arena
Mon, 11/7/22 - 10:49 am
BioMind Labs
clinical trials
BMND01
treatment-resistant depression
Lusaris Launches with $60M to Advance Psychedelic-Based Depression Therapeutic
BioSpace
Thu, 11/3/22 - 11:00 am
Lusaris Therapeutics
funding
LSR-1019
depression
treatment-resistant depression
Abbott Looks to Treat Severe Depression with DBS
Medical Devices and Diagnostics Industry
Tue, 07/12/22 - 11:27 pm
Abbott Labs
deep brain stimulation
treatment-resistant depression
depression
devices
Medtech
First patient dosed in second Phase 2 add-on Ketamine Trial in Treatment-Resistant Depression (TRD)
Drugs.com
Wed, 06/8/22 - 11:02 pm
HMNC Brain Health
Develco Pharma
clinical trials
KET01
treatment-resistant depression
ketamine
AbbVie adds to Vraylar data as FDA considers depression use
Pharmaforum
Tue, 05/24/22 - 10:43 am
AbbVie
Vraylar
FDA
clinical trials
treatment-resistant depression
Largest psilocybin trial finds the psychedelic is effective in treating serious depression
Stat
Tue, 11/9/21 - 11:37 pm
psychedelic drugs
psilocybin
treatment-resistant depression
COMPASS Pathways
clinical trials
Aditum Bio Announces Formation of Ancora Bio, to Focus on Treatment-Resistant Depression
BioSpace
Wed, 06/30/21 - 10:58 am
Aditum Bio
Ancora Bio
treatment-resistant depression
Joe Jimenez
FDA expands use of controversial J&J antidepressant
Beckers Hospital Review
Wed, 08/5/20 - 12:01 am
FDA
JNJ
Spravato
treatment-resistant depression
major depressive disorder
ketamine
Takeda Grants License To Neurocrine Biosciences For Seven Pipeline Programs
NASDAQ
Tue, 06/16/20 - 10:48 am
Takeda
Neurocrine Biosciences
psychiatry
schizophrenia
treatment-resistant depression
anhedonia
Compass raises $80M to take magic mushroom drug toward phase 3
Fierce Biotech
Mon, 04/27/20 - 09:25 am
COMPASS Pathways
psilocybin
magic mushrooms
treatment-resistant depression
Axsome Therapeutics' Key Drug Candidate Whiffs in Phase 3 Trial
Motley Fool
Mon, 03/30/20 - 08:15 pm
Axsome Therapeutics
AXS-05
treatment-resistant depression
clinical trials
Upcoming events – Axsome’s depression data and Eli Lilly’s IL-10 in lung cancer
EP Vantage
Fri, 12/13/19 - 11:02 am
Axsome Therapeutics
AXS-05
treatment-resistant depression
depression
Eli Lilly
pegilodecakin
lung cancer
Sage Therapeutics Updates Pipeline to Focus on Treatment-Resistant Depression
BioSpace
Thu, 07/25/19 - 07:07 pm
SAGE Therapeutics
treatment-resistant depression
SAGE-217
J&J's Esketamine Fails to Meet Endpoint in Phase III Study
Yahoo/Zacks.com
Tue, 09/25/18 - 09:45 am
JNJ
clinical trials
esketamine
treatment-resistant depression
Psilocybin Therapy for Treatment-Resistant Depression is Being Taken Seriously by Regulators as FDA Gives Go-Ahead to Clinical Trial
Xtalks
Fri, 08/24/18 - 11:03 am
COMPASS Pathways
FDA
psilocybin
treatment-resistant depression
Albany Molecular says Bristol-Myers stops developing depression drug
Reuters
Mon, 08/12/13 - 05:01 pm
Albany Molecular Research
Bristol-Myers Squibb
BMS-820836
treatment-resistant depression
depression